Triple negative breast cancer (TNBC) & Other Solid tumors

Product Candidate / PROGRAM Drug substance Indication Discovery Pre-clinical Phase 1 Phase 2 Phase 3/ Pivotal Commercial Rights
eryaspase (GRASPA® (1)) Asparaginase TNBC 1L
Solid tumors

Following the positive clinical data in pancreatic cancer, ERYTECH intends to develop eryaspase for the treatment of triple negative breast cancer and selected other solid tumor indications. We are investigating the possibility to conduct clinical trials in one or more Non-Hodgkin Lymphoma (NHL) indications.